In re Empyrean Biosciences, Inc. Securities Litigation

219 F.R.D. 408, 2003 U.S. Dist. LEXIS 12544, 2003 WL 23000944
CourtDistrict Court, N.D. Ohio
DecidedJuly 2, 2003
DocketNo. 1:02 CV 1439
StatusPublished
Cited by4 cases

This text of 219 F.R.D. 408 (In re Empyrean Biosciences, Inc. Securities Litigation) is published on Counsel Stack Legal Research, covering District Court, N.D. Ohio primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
In re Empyrean Biosciences, Inc. Securities Litigation, 219 F.R.D. 408, 2003 U.S. Dist. LEXIS 12544, 2003 WL 23000944 (N.D. Ohio 2003).

Opinion

Memorandum of Opinion and Order

GAUGHAN, District Judge.

INTRODUCTION

This matter is before the Court upon Defendants’ Motion to Dismiss the Second Consolidated Amended Class Action Complaint and to Strike the Declaration of Laurence M. Rosen. (Doc. 31). Also before the Court is Plaintiffs’ Motion and Notice of Motion for Judicial Notice of Facts. (Doc. 36). For the following reasons, Defendants’ Motion to Strike is GRANTED. Defendants’ Motion to Dismiss is DENIED at this time and plaintiffs are hereby GRANTED leave to amend the complaint. Plaintiffs’ Motion is UNOPPOSED and GRANTED.

FACTS

This is a class action securities fraud case brought pursuant to the Private Securities Litigation Reform Act (hereafter “PSLRA”), 15 U.S.C. § 78u-4. This Court dismissed plaintiffs’ First Amended Complaint by order dated February 26, 2003, as a result of plaintiffs’ failure to comply with the PSLRA’s heightened pleading requirements. Plaintiffs, however, were granted leave to amend. Thereafter, plaintiffs filed their Second Amended Complaint, which is currently before this Court.1

Upon review of the Second Amended Complaint, the Court notes that it contains, in large part, a recitation of the same allegations set forth in the First Amended Complaint. Attached to the Second Amended Complaint, however, is the Declaration of Laurence M. Rosen. Mr. Rosen is plaintiffs’ counsel in this case. The declaration provides a detailed account of an investigation he conducted into various matters relating to plaintiffs’ claims. For example, Mr. Rosen details conversations he had with a confidential source, and then sets forth the contents of those conversations in his declaration. In addition, Mr. Rosen details numerous other conversations he had with various individuals concerning plaintiffs’ claims. The declaration is over fifteen pages long, contains 47 numbered paragraphs and purports to incorporate 13 exhibits. The factual support provided by Mr. Rosen is not alleged in the Second Amended Complaint. Instead, plaintiffs attempt to “incorporate” his declaration into the complaint and then cite to various paragraphs in the declaration as factual support for their assertions. For example, paragraph 108 of the complaint reads,

On March 13, 2001, Empyrean issued a press release over the PR Newswire falsely stating the “Empyrean has exclusive marketing rights to the GEDA Plus microbicidal contraceptive gel now in phase III clinical trials in Brazil.” The March 13, 2003 press release was false because the Phase III trials had never actually begun and were not being performed and Empyrean either knew this fact or was reckless in not confirming the truth about the trials. (Rosen Dec. ¶¶ 26-29).

Paragraphs 26 through 29 then refer the reader to over two pages of facts purporting to support this allegation. For example, paragraph 26 of the declaration provides,

In August of 2002, I received a telephone call from an individual who identified himself as Kerry Flowers. He stated that he was an attorney for International Bioscience Corp. He said he worked for a law firm in New Jersey by the name of Krug-man and Kalies. He told me that IBC had learned of the'class action against Empy[410]*410rean and that since it was a large shareholder it was considering joining the lawsuit as a plaintiff. [...] I[],asked him point blank: “But no patients were ever enrolled in any Phase III trials in Brazil and Geda Plus gel was never given to any patients as part of a clinical trial in Brazil?” Mr. Flowers responded, “That’s true.” Mr. Flowers confirmed that no patients were ever enrolled in any Phase III clinical study of Geda Plus in Brazil.

In sum, it appears plaintiffs have attempted to provide evidentiary support for the allegations in the complaint by attaching a declaration from their attorney.

Defendants move to strike the Rosen Declaration. Plaintiffs oppose defendants’ Motion and request that, in the event defendants’ Motion to strike is granted, this Court grant them leave to amend the complaint. According to plaintiffs, they will simply “transfer” the “allegations” set forth in the declaration into the body of the complaint.

• In addition, plaintiffs move for judicial notice of two documents consisting of FDA guidelines. Defendants do not oppose plaintiffs’ motion and, accordingly, the motion is hereby GRANTED.

DISCUSSION

Defendants initially argue that plaintiffs improperly attached an affidavit2 to the complaint and that such a document is not a “written instrument” that may be considered by the Court as part of a pleading pursuant to Federal Rule of Civil Procedure 10(c). In their reply brief, however, defendants appear to have abandoned the argument that the court may never consider affidavits. Instead, defendants argue that an affidavit from plaintiffs’ counsel, which “fills in” missing factual allegations not contained in the complaint, should not be considered by the Court. Defendants also argue that the Court should not consider the affidavit because it will transform plaintiffs’ attorney into a fact witness in the case and, therefore, violates certain disciplinary rules.

Plaintiffs argue that affidavits may be considered by the Court pursuant to Rule 10(c) and point out that a majority of courts allow this practice. In addition, plaintiffs argue that the declaration does not violate any disciplinary rule. According to plaintiffs, there is no need for counsel to be called as a witness since defendants will be able to depose the various individuals referred to in the declaration.

Rule 10(c) provides that “[a] copy of any written instrument which is an exhibit to a pleading is a part thereof for all purposes.” There is a split among the circuits as to whether an affidavit qualifies as a “written instrument” for purposes of Rule 10(c), and the Sixth Circuit has not specifically addressed this issue in detail.

In Rose v. Bartle, 871 F.2d 331 (3d Cir.1989), the Third Circuit analyzed whether an affidavit constitutes a “written instrument” for purposes of Rule 10(e). In Rose, two of the plaintiffs attached an affidavit to their amended complaint. The court held that the affidavit could not be considered as part of the pleading. The court reasoned,

The case law demonstrates, however, that the types of exhibits incorporated within pleadings by Rule 10(c) consist largely of documentary evidence, specifically contracts, notes, and other ‘writingfs] on which [a party’s] action or defense is based.’ ‘Lengthy exhibits containing. . .evidentiary matter should not be attached to the pleadings.’ [¶]... ] We do not believe that an affidavit is a ‘written instrument’ as that term is used in Rule 10(c). To hold otherwise would elevate form over substance by drawing a distinction between an affidavit filed with an answer and an affidavit filed with a motion to dismiss under Rule 12(b)(6).

Id. at n. 3.

Relying on Rose, the Western District of New York concluded in Murphy v. Cadillac Rubber & Plastics, Inc., 946 F.Supp.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Steverson v. Walmart
M.D. Tennessee, 2019
Barnard v. Lackawanna County
194 F. Supp. 3d 337 (M.D. Pennsylvania, 2016)

Cite This Page — Counsel Stack

Bluebook (online)
219 F.R.D. 408, 2003 U.S. Dist. LEXIS 12544, 2003 WL 23000944, Counsel Stack Legal Research, https://law.counselstack.com/opinion/in-re-empyrean-biosciences-inc-securities-litigation-ohnd-2003.